MAIN ARTICLE
Two research programmes reach an international forum
According to a November 4 announcement by CK Life Sciences, the Society for Immunotherapy of Cancer accepted two Sequencio abstracts for its 41st annual meeting, held November 4–8 in Phoenix. Presentation gives the findings an opportunity for scientific scrutiny and discussion with potential partners; it does not mean that clinical efficacy has been established or a medicine approved.
CKLS118 is an investigational circular RNA therapeutic vaccine directed against TROP2. Sequencio tested it alongside anti-PD-1 therapy, a class of drugs intended to restore immune cells’ ability to attack cancer. In one TROP2-positive tumour model, growth inhibition reached 74.7% and 88.9% at two combination doses, compared with 28.9% and 68.6% for the corresponding anti-PD-1 doses alone.
Immune signals are not yet patient outcomes
CKLS202 follows a different strategy involving PD-L1 and PRAME, a tumour-associated antigen found in several cancers. The company reported about 65% inhibition of tumour growth in its preclinical work, accompanied by indicators of immune activity inside tumours.














